

UNCLASSIFIED

AD NUMBER
ADB263560
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Jun 2000. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMR ltr, dtd 15 May 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-99-1-9109

TITLE: The Cellular Targets of Estrogen in Mammary Ductal
Development

PRINCIPAL INVESTIGATOR: Peter Kushner, Ph.D.

CONTRACTING ORGANIZATION: University of California, San Francisco
San Francisco, California 94143-0962

REPORT DATE: June 2000

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government
agencies only (proprietary information, Jun 00). Other requests
for this document shall be referred to U.S. Army Medical Research
and Materiel Command, 504 Scott Street, Fort Detrick, Maryland
21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20010220 023

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-99-1-9109

Organization: University of California, San Francisco

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Kath Mm Wald

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE June 2000	3. REPORT TYPE AND DATES COVERED Annual (1 Jun 99 - 31 May 00)	
4. TITLE AND SUBTITLE The Cellular Targets of Estrogen in Mammary Ductal Development		5. FUNDING NUMBERS DAMD17-99-1-9109	
6. AUTHOR(S) Peter Kushner, Ph.D.		8. PERFORMING ORGANIZATION REPORT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California, San Francisco San Francisco, California 94143-0962 E-MAIL: kushner@itsa.ucsf.edu			
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES <p style="text-align: center;">Report contains color photos</p>			
<small>Distribution authorized to U.S. Government agencies only (proprietary information, Jun 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.</small>			2b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) It is known that the actions of estrogen in mammary development are mediated primarily by the estrogen receptor alpha, but it is not known which estrogen receptors, those in stroma or those in epithelium mediate mammary development. Our purpose is to probe this question by constructing transgenic mice in which wild type human estrogen receptor (hER) and mutants of the receptor that are super-active either at the classical ERE or alternative AP-1 pathway are selectively expressed in epithelium or stroma. A further purpose is to explore the importance of the AP-1 versus the classical pathway in estrogen effects on ductal development. In the first year of this project we have constructed vectors for expression of wild type and mutant human estrogen receptors in the mammary epithelium of transgenic mice, and have made a pilot study of the effects of expressing these receptors in the reproductive epithelium of transgenic mice. The mice transgenic for a human ER super-active at AP-1 show gross abnormalities and hyperproliferation of the reproductive tract.			
14. SUBJECT TERMS Breast Cancer, estrogen receptor, ap-1, stroma, epithelium		15. NUMBER OF PAGES <p style="text-align: center;">30</p>	
		16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT <p style="text-align: center;">Unlimited</p>

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....

SF 298.....Page 2.....

Table of Contents.....Page 3.....

Introduction.....Page 4.....

Body.....Page 5-10.....

Key Research Accomplishments.....Page 11.....

Reportable Outcomes.....Page 12.....

Conclusions.....Page 13.....

References.....Page 14.....

Appendices...One manuscript, unpublished and confidential...

Introduction:

The subject of this research project is the action of estrogen in mammary ductal development. It is known that the actions of estrogen in mammary development are mediated primarily by the estrogen receptor alpha, but it is not known which estrogen receptors, those in stroma or those in epithelium mediate mammary development. Our purpose is to probe this question by constructing transgenic mice in which wild type human estrogen receptor (hER) and mutants of the receptor that are super-active either at the classical ERE or alternative AP-1 pathway are selectively expressed in epithelium or stroma. A further purpose is to explore the importance of the AP-1 versus the classical pathway in estrogen effects on ductal development.

Body:

We divided up this application into two tasks:

Task 1. To Analyze whether estrogen treatment causes mammary ductal hyperplasia in transgenic mice in which human estrogen receptor and pathway specific super active variants thereof are over-expressed in mammary stromal fibroblasts, adipocytes and epithelial cells (months 1-36).

-Construct vectors that will allow expression of human ER and super-active variants of ER in the mammary stromal fibroblasts and other mammary tissues of transgenic mice (months 1-12).

-Create mice carrying the expression vectors for human ER and test them for expression of human ER in mammary gland and other tissues (months 6-24).

-Determine whether mice that express high levels of either wild type or super-active hERs in mammary compartments develop ductal hyperplasia (months 18-36).

Task 2. To determine whether ERKO transgenics that have hER expression in specific tissues of the mammary gland display restored mammary ductal development in response to estrogen

-Establish a colony of ERKO +/- mice (months 1-12)

-Bred these mice to transgenics expressing human ER (months 12-24)

-Analyze mammary development in ERKO -/- transgene offspring (months 18-36)

For the first year we have made progress on three fronts, vector construction, pilot studies in mice, and establishment of the ERKO colony,

Vectors. In our initial constructions we have used the wild type human estrogen receptor, (hER) and a super active mutant, hER K206A, which increases the efficiency of ER action at AP-1 target genes, but not increase the efficiency of ER at classical EREs. The behavior of this mutant in transfected cells in culture is shown in the appended manuscript by Andereg et al.. At AP-1 containing target genes, such as the collagenase gene, and the Cylin D1 gene, the K206A hER is more than 10 fold more efficient than wild type in inducing gene expression. Yet, if anything, the K206A mutant is weaker than wild type in inducing gene expression at target genes with an ERE.

We have made two sets of vectors that should direct expression of wild type and super-active human estrogen receptors to the epithelial cells of the mammary gland of transgenic mice. Each of these uses the Mouse Mammary Tumor Virus (MMTV) promoter to drive transcription. One set uses a standard MMTV transgene vector developed by Dr. William Muller and his colleagues and that has been used for making numerous transgenic mouse lines that express various proteins in mammary epithelium (Cardiff and Muller, 1993, (Dankort and Muller, 1996, Guy, et al., 1994, Li, et al., 1997). The map of the vector is show in figure 1 overleaf. Notice that the vector uses the SV40 small t antigen splice and poly adenylation signal that has been claimed to limit expression somewhat in transgenic mice.

Although these vectors do drive expression of human ER properly in transfected mammary cells as shown in the figure below, their level of expression is low. To ensure high level expression, we have therefore undertaken the development of an improved vector system, which is again outlined in the figure. The improved vector has the beta globin small intron proceeding the hER

coding sequence which is followed by the human growth hormone poly A addition signal and is shown in Figure 2 overleaf. A classical study by Brinster and colleagues suggests that the small intron and growth hormone poly A greatly aid expression in transgenic mice (Brinster, et al., 1988). In addition, we have flanked the expression cassette on both sides with an insulator sequence derived from the chicken beta globin gene. Although this sequence has not been tested in transgenic mice, it does confer much more reliable expression in stable transfection into tissue culture cells (Bell, et al., 1999).

The vectors driving wild type and mutant hERs are currently being injected into mice to create the transgenes.

Pilot Study. We have made a pilot study of our strategy to overexpress human ERs in mice in collaboration with Jeffrey Arbeit's lab here at UCSF. Dr. Arbeit heads the transgenic facility at the UCSF Cancer Research Center and his own lab has had extensive experience with the use of the Keratin 14 gene promoter in transgenic mice (Arbeit, et al., 1996). The K14 promoter drives expression in selected epithelial tissues including the skin and the lining of the lower reproductive tract in females. We therefore made expression vectors of hER and K206A driven by the K14 promoter and introduced these vectors into transgenic mice. The results of this experiment are reported in detail in the appended manuscript.

In brief, human wild type ER was very well expressed in the cervical and vaginal epithelium of the single line of mice with this construct. No aberrations could be seen either in gross morphology of the reproductive organs, or in histological examination. There was a small and variable increase in proliferation, evidenced in staining with antibody to the Proliferating Cell Nuclear Antigen (PCNA), and an increase in Cylin D1 expression in the epithelium. Two lines of mice carried the K14:K206A transgene gave lower levels of expression of the hER.

However, in contrast to the mice expressing wild type hER, the K206A mice showed gross aberrations of the reproductive tract. In both lines the cervix and vagina of aged animals is

greatly enlarged (5-10 times normal). This appears due to hyperproliferation of the epithelial cells as indicated by PCNA staining. There is a dramatic increase in Cyclin D1 expression throughout the epithelium.

Since the wild type ER was without these effects, yet was expressed at a higher level than K206A, these results suggest that a feature of the K206A mutant must be responsible for the effects on the reproductive tract. We believe that these are due to the ability of this receptor to activate target genes with AP-1 sites. These results are thus in line with expectations that the ER-AP-1 pathway is important for proliferative effects of estrogen.

ER alpha knock out mice (alpha ERKO) . We have received a breeding pair ERKO heterozygous mice from Dennis Lubahn and are building up the colony (Lubahn, et al., 1993).

Figure 1







Figure 2



Key Research Accomplishments:

- Demonstrated that a point mutation in the human estrogen receptor allows the receptor to be super-active in just the pathway of action that leads to target genes with AP-1 elements.
- Demonstrated that expression in the reproductive tract of mice of the human estrogen receptor super-active at AP-1 targets leads to hypertrophy and hyperplasia.

Reportable Outcomes:

Manuscripts

One manuscript to be submitted, "The estrogen receptor alpha mutant, K206A, superstimulates AP-1 trans-activation and produces cervico-vaginal hypertrophy and hyperplasia in transgenic mice." This is attached.

Abstracts-

Nuclear Receptors 2000, "A point mutation in the ER DBD separates the AF-dependent from the AF-independent pathways of AP-1 stimulation and generates an abnormal phenotype in transgenic mice."

R. Uht, B. Anderegg, P. Webb, C. Anderson, J. Arbeit, and P. Kushner.

Talks.

Nobel Symposium- Karlskoga Sweden June 1999

Gordon Research Conference on Breast and Prostate Cancer August 1999

Merck Symposium on Estrogen Action, Philadelphia November 1999

University of Colorado Health Sciences Cancer Research Mini Symposium, March 2000

University of California San Francisco, Breast Oncology Group Seminars, June 2000

Patents;

One patent has been applied for. "Expression of human steroid receptors in transgenic animals. UC case no. 99-382 Jeffrey M. Arbeit et al. Inventors.

US Patent Application No. 09/365,614

Conclusion:

The conclusions from this first year of research are of course tentative. We can say that point mutations in a single amino acid in the DNA binding domain of the human estrogen receptor confer super-activity selectively on AP-1 targets, without conferring super-activity at target genes with classical EREs. This pattern is seen in a variety of cells in tissue culture.

When expressed in the epithelial cells of the reproductive tract of transgenic mice the mutant human ER confers hypertrophy and hyperplasia of the cervix and vaginal epithelium. Of course, we are eager to see what will happen when the same receptors are expressed in the mammary gland of transgenic mice. Then, we will be able to draw some important conclusions with regard to estrogen action in breast cancer. However, from the results at hand it appears that stimulation of the ER-AP-1 pathway leads to turn on of Cyclin D1, hyperproliferation, hyperplasia, and hypertrophy of the lower reproductive tract. Importantly, the wild type ER does not have these effects, suggesting that the AP-1 ER pathway is alone responsible.

"So What?" If expressing the K206A mutant human ER in the mammary gland also leads to hyperproliferation, it will suggest that in hormone dependent breast cancer and premalignant states, the pathway of hormone action leads to AP-1 regulated target genes. "So What?" Well once we know the pathway, we can take steps to block hormone action, and maybe some day develop better antiestrogens to treat or prevent breast cancer. Do we still want to ask, "So what?"?

References

- Cardiff, R. D. and Muller, W. J. (1993) Transgenic mouse models of mammary tumorigenesis. *Cancer Surv*, 16,97-113
- Dankort, D. L. and Muller, W. J. (1996) Transgenic models of breast cancer metastasis. *Cancer Treat Res*, 83,71-88
- Guy, C. T., Muthuswamy, S. K., Cardiff, R. D., Soriano, P. and Muller, W. J. (1994) Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. *Genes Dev*, 8,23-32
- Li, B., Rosen, J. M., McMenamin, B. J., Muller, W. J. and Perkins, A. S. (1997) neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. *Mol Cell Biol*, 17,3155-63
- Brinster, R. L., Allen, J. M., Behringer, R. R., Gelinas, R. E. and Palmiter, R. D. (1988) Introns increase transcriptional efficiency in transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*, 85,836-40
- Bell, A. C., West, A. G. and Felsenfeld, G. (1999) The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. *Cell*, 98,387-96
- Arbeit, J. M., Howley, P. M. and Hanahan, D. (1996) Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. *Proc Natl Acad Sci U S A*, 93,2930-5
- Lubahn, D. B., Moyer, J. S., Golding, T. S., Couse, J. F., Korach, K. S. and Smithies, O. (1993) Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. *Proc Natl Acad Sci U S A*, 90,11162-6

The estrogen receptor α mutant, K206A, superstimulates AP-1 *trans*-activation and produces cervico-vaginal hypertrophy and hyperplasia in transgenic mice

Birgit Anderegg^{1,4}, Rosalie M. Uht^{1,2,4}, Adriana C. Rossi, Kristen E. Hilty², Paul Webb², Carol M. Anderson^{2,4}, D. Barry Starr³, Peter J. Kushner² ⁵& Jeffrey M. Arbeit⁵

¹both authors have contributed equally to this publication

⁵ *co-corresponding authors,*

UCSF Comprehensive Cancer Center, University of California San Francisco, 2340 Sutter St., Box 0808, San Francisco CA 94115; ²Metabolic Research Unit, ³Department of Biochemistry, University of California San Francisco, Box 0540, San Francisco CA 94143

⁴Present addresses: Institute of Pathology, LMU Muenchen, Thalkirchner Strasse 36, D-80337 Muenchen, Germany (B.A.); Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA (R.M.U.); Program in Molecular and Cellular Biology, University of California, Berkeley, CA (C.M.A.); Gene Labs (address ?) (D.B.S)

Estrogen receptor ER α activates gene expression by binding estrogen response elements in DNA or by potentiating transcription factors such as AP-1. The latter pathway has been implicated in estrogen stimulation of cell proliferation. We show here that a point mutation in the human ER α , K206A, while leaving transcriptional activation through estrogen response elements relatively unchanged, dramatically increases its ability to stimulate transcription through

AP-1. To determine the effect of selectively amplifying the ER pathway through AP-1 , we generated transgenic mice expressing human ER α .K206A via the keratin 14 promoter, which confers expression in epithelial cells including those of the lower reproductive tract. Female mice expressing hER α . K206A have vaginal and cervical hypertrophy with vaginal squamous hyperplasia by 12 months of age. Non-transgenic controls and mice expressing the wild type receptor via the keratin 14 promoter failed to develop such reproductive tract abnormalities. These results suggest that overstimulation of alternative target genes by ER leads to dysregulated growth in an estrogen target tissue.

Estrogen receptors (ERs) activate expression of classical target genes that contain estrogen response elements (EREs) and also alternative target genes that contain AP-1 sites ¹⁻³, SP-1 sites ^(4, and refs therein), and others (see, e.g. ⁵). The ER binds directly to EREs through its DNA binding domain (DBD) and activates transcription through the recruitment of coactivators via its activation functions, the constitutive AF-1 in the amino terminal domain, and the hormone activated AF-2 in the C-terminal ligand binding domain (LBD). ER activates at AP-1 by protein-protein interactions and is independent of DNA binding. ER action at AP-1 is usually less dramatic than at consensus EREs, but may nonetheless be important as the target genes implicated in estrogen stimulation of cell proliferation, such as the Cyclin D1 gene, have AP-1 or related sites and not EREs ^{6,7}. ER-estrogen stimulation through AP-1 is also mediated by the ER AF-1 and AF-2 ². The ability to stimulate transcription at AP-1 sites is unique to the ER among nuclear receptors, most of which repress transcription at AP-1 sites in the presence of hormone. A point mutation at the base of the first zinc finger of the DBD in the glucocorticoid (GR), thyroid (TR) and other receptors, however, has been shown to convert each of them from an inhibitor to a stimulator of AP-1 activity ⁸. We therefore sought to determine the effect of the homologous mutation in the ER α , ER.K206A (Fig. 1A).

ER α K206A super-stimulated a target genes with an AP-1 site, such as the human collagenase promoter (Fig. 1b) or the Cyclin D1 promoter (not shown). In each case

K206A was almost ten fold more active than wild type ER. ER α .K206A had normal activity at a variety of ERE target genes including the collagenase promoter with the AP-1 site substituted by a consensus ERE (Fig. 1b right panel), and was weaker than normal at SP-1 targets (data not shown). The K206A mutant is super active in a wide variety of cell types (Fig. 1C). We conclude that, the K206A mutation confers super-activity at AP-1 targets, but not at an ERE.

Mutation of the AF-2 function eliminates the ability of K206A to activate at AP-1, in cells in which ER AF-2 predominates (Fig. 1D). The mutation does not interfere with expression of the mutant receptor as the AF-2 mutant of K206A, like similar ER mutants, is a dominant negative inhibitor of ER action at an ERE (data not shown) In cell types in which ER AF-1 is strong, K206A requires the AF-1 function for full activity (data not shown). Thus K206A stimulates AP-1 targets, through its AF functions, similar to the wild type ER.

Activation of AP-1 target genes is a critical event in proliferation, and tumor genesis. For example, transgenic mice expressing a dominant negative mutant of the AP-1 family member c-jun in the epidermis have reduced skin thickness, and are protected from chemically induced epidermal carcinogenesis. Stimulation of AP-1 targets by estrogen- bound ER has been implicated in the stimulation of cell growth by estrogen (1,2,9,10, and refs therein). Since the squamous epithelium outlining the vagina and lower cervix proliferates in response to estrogen, we investigated the effect of the K206A mutation on this response. We engineered mice in which human ER α (wild type) and ER α .K206A were targeted to the cervico-vaginal squamous epithelium, by expression through the human keratin 14 (K14) promoter (K14-ER α and K14-ER α .K206A, respectively) (Fig. 2).

Two independent lines of each transgenic model, K14-ER α and K14-ER α .K206A, were established. Female mice were aged for up to 24 months. Thirty of a total of 36 (83%) K14-ER α .K206A females aged for more than 6 months spontaneously developed striking perineal swelling and distention (Fig. 2a, bottom). A similar phenotype was never observed in age-matched K14-ER α transgenic mice or non-transgenic controls (Fig. 2a, top).

Dissection revealed that the K14-ER α .K206A transgenic females developed vagino-cervical hypertrophy and prolapse, that in some instances was pronounced (Fig. 2 b right panels). Histological sectioning revealed epithelial hyperplasia as well as stromal fibrosis (Fig. 2c). No histopathological abnormalities were evident in non-transgenic or K14-ER α transgenic animals.

To rule out that development of the observed hyperplastic changes in K14-ER α .K206A transgenic mice compared to K14-ER α transgenic animals was due to differential transgene expression, immunohistochemistry (IHC) was performed using a human ER α -specific antibody. Transgene-expressing nuclei were much more frequent in the vagino-cervical epithelium of K14-ER α than K14-ER α .K206A transgenic mice (Fig. 2c). Western blotting and immunostaining of cells transfected with either human ER α or human ER α .K206A determined that the antibody used for IHC had equivalent sensitivity to detect either transgene (data not shown). Consequently, the abnormal phenotype of transgenic mice bearing the mutant ER α cannot be explained by higher or more widespread distribution of transgene expressing cells in K14-ER α .K206A than in K14-ER α transgenic mice. We conclude that the striking phenotype of the K206A mice is due to the mutation itself.

K206A mice have an increase in epithelial cell layers and papillations at the epithelial-stromal interface (Fig. 3a) and have higher and more frequent expression of proliferating cell nuclear antigen (PCNA) compared to age-matched K14-ER α transgenic and non-transgenic control mice (Fig. 3b). Therefore, the development of an abnormal vaginal phenotype in K14-ER α .K206A transgenic mice 12 months of age or older is likely due to increased epithelial proliferation.

To determine whether ER α .K206A increased transcription through an AP-1 site in cervico-vaginal epithelium of transgenic mice as previously shown in reporter assays *in vitro*, we determined protein expression of cyclin D. Cyclin D1 expression is known to be regulated by estrogen despite the lack of classical EREs as noted above. Cyclin D protein expression was in good concordance with the PCNA data: In K14-ER α .K206A cervico-vaginal epithelium Cyclin D was more abundant and more widely distributed than in non-transgenic or in wild type ER α transgenic tissues.

Cyclin D was expressed in several suprabasal cell layers (Fig. 3c, top). Thus, ERK206A expression leads to increased cyclin D expression *in vivo*. This observation accords both with our *in vitro* findings of increased *trans*-activation of AP-1-responsive genes through ER α .K206A expression as well as the recently proposed model of cyclin D1 expression depending on AP-1 factors.

We describe a mutant in the human ER α with over-activation of transcriptional activity at AP-1 sites, but normal activity at EREs. When expressed in squamous epithelial cells of transgenic mice the mutant ER elicits markedly increased proliferation of the cervico-vaginal epithelium, a known estrogen target. Since the wild type human ER does not confer such a phenotype, we conclude that a feature of the mutant, most likely its selectivity for AP-1 and related targets is responsible. Thus, in accordance with the predictions made from studies of estrogen action in cultured cells ER action at alternative response elements plays an important role in mediating the proliferative effects of estrogen *in vivo*.

Gain of AP-1 function has been implicated in cervical carcinogenesis. The data presented here, that ER α signaling at AP-1 sites in cervico-epithelial squamous cells contributes to increased proliferation, may indicate an association of ER action at AP-1 with neoplastic events of the cervix. The transgenic mutant ER α mouse model described here may thus foster development and validation of pharmacological agents interrupting ER α /AP-1 interactions for use in chemopreventive or antineoplastic therapies.

Material and Methods

Cell lines

Rosalie's transfected lines; MCF-7

Plasmids and transgene cloning

The promoter/reporter constructs Δ Coll73:LUC and ERE II TK:LUC and the expression plasmid for the fully wild type human ER α (derived from HEG0) have been previously described. The K206 mutation was introduced into human ER α by

site-directed mutagenesis. The mutation was verified by sequence analysis. α -K206A was generated using a α -K206A fragment of ER α .K206A into α -K206A (originally HE19 needs further explanation?) digested with. ER α .K206A mAF-2 was generated by α -K206A

To construct K14-ER α and K14-ER α .K206A, the FGF coding sequence was removed from α -K206A by a SmaI digest to generate a K14-driven expression vector. ER α and ER α .K206A were removed from pSG5 expression vectors by an EcoRI digest and blunt-end ligated into the K14 construct. The identities of the plasmids were confirmed by sequencing. K14-ER α and K14-ER α .K206A fragments were excised enzymatically (enzymes) and purified for oocyte injection (protocol).

Transient transfections

Transient transfections were performed as previously described. Briefly, DNA was transfected into cells by electroporation. Transfection efficiency was monitored by co-transfecting an actin- β gal construct. Relative Light Units represent luciferase light units divided by β gal activity.

Transgenic mice

Transgenic mice were created by microinjecting the K14-ER α .K206A or K14-ER α construct into one-cell FVB/n embryos. At the age of 21 days, pups were genotyped by PCR analysis of tail tip DNA using a β -globin-specific primer pair (5'-AGAAAAGAAGGCATGAACATGG-3' and 5'-GTGAGTTTGGGGACCCTTGAT-TGT-3'). Thermal cycling was carried out at 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds for 35 cycles in a GeneAmp PCR System 9700 (PE Applied Biosystems, Norwalk, CT). The expected xx bp fragment was visualized on a 2% agarose gel stained with ethidium bromide.

Histopathology and immunohistochemistry

As described previously, mice were sacrificed by perfusion of the ascending aorta with 3.75% paraformaldehyd under Avertin anesthesia. Reproductive tracts were dissected and post-fixed overnight at 4°C. After removal of the posterior vaginal wall, tissues were rinsed in phosphate buffered saline (PBS), dehydrated through graded alcohols and xylene, embedded in paraffin with the cut vaginal surface facing downward, and 5_μm sections were stained with hematoxylin/eosin (Sigma).

PCNA IHC was carried out as described previously (. Briefly, 5_μm tissue sections were deparaffinized, rehydrated and subjected to antigen retrieval in 10mM citrate buffer, pH 6.0 by microwaving them for two 5-minute high-power pulses. Sections were washed,blocked in 3% bovine albumin (Sigma) in PBS, and subsequently exposed to a 1:200 dilution of mouse anti-PCNA monoclonal antibody (Biogenex). Signal development was performed by using a biotinylated goat anti-mouse IgM secondary antibody (diluted 1:200; Vector), the Vector Elite immunoperoxidase reagent (Vector), and working-strength NovaRed solution (Vector) as a substrate. Sections were counterstained with Gill's #1 hematoxylin (Sigma).

Human ERα IHC was carried out similarly, using a 1:200 dilution (in 0.2% bovine albumin) of anti-human ERα monoclonal antibody D75 (Greene G, Nolan C, Engler J, Jensen E (1980). Monoclonal antibodies to human estrogen receptor. Proc. Natl. Acad. Sci. USA, 77:5115-5119) and biotinylated anti-rat IgG secondary antibody (1:200 in 0.2% bovine albumin; Vector).

Cyclin D1 IHC was performed similar to PCNA IHC, but additionally included blocking of endogenous peroxidase by a 20-minute incubation in 3% hydrogen peroxide in methanol right after dehydration of the tissue. A 1:500 dilution of an anti-Cyclin D polyclonal antibody (Upstate Biotechnology) and a 1:200 dilution of a biotinylated anti-rabbit IgM (Vector) were used. 3,3'-diaminobenzidine (Sigma) served as substrate. Sections were not counterstained.

Western blotting

Mice were sacrificed by cervical dislocation, reproductive tracts dissected and fallopian tubes removed. The remaining tissue was snap-frozen and grinded down in chilled standard lysis buffer (1% NP-40/0.1M NaCl/2mM EDTA/0.1M Tris, pH 8.0 with 1_1/ml aprotinin (Sigma), 10_1/ml polymethyl sulflfluorid (Sigma), 0.5_1/ml 1M DTT (Sigma), and 10_1/ml NaF (Sigma)). Samples were agitated at 4°C for 60min, then cleaned from cell debris by centrifugation at 14,000rpm/4°C. MCF-7 cells were washed twice with PBS prior to lysis and cleaning of the sample. 20_g whole cell extract/protein sample as well as 5_g Rainbow Standard RPN 800 (Amersham) were separated on a 7.5% SDS/polyacrylamide gel and transferred onto a polyvinylidene difluoride membrane. After blocking with PBS/5% milkpowder/0.1% Tween 20, the filter was hybridized with the polyclonal anti-human ER α antibody HC-20 (Santa Cruz) diluted 1:500 in PBS/0.1% Tween20 at room temperature and horseradish peroxidase-conjugated anti-rabbit IgG (Amersham) diluted 1:2,000 in PBS/0.1% Tween 20. The membrane was thoroughly washed in PBS/0.1% Tween 20 and developed by enhanced chemiluminescence (ECL) (Amersham).

Acknowledgements: We thank David A. Elson for excellent technical assistance and Dr. Geoffrey Greene for generously providing the D75 antibody.

Correspondence and requests for materials should be addressed to J.M.A. (e-mail: arbeit@cc.ucsf.edu) or P.J.K. (e-mail: kushner@itsa.ucsf.edu).

Figure legends

Fig. 1 A point mutation in ER α , K206A, results in super-activation at an AP-1 site but not at an ERE. *a*, **Location** of the ER α .K206A mutation in the first zinc finger of the DNA binding domain., *b*, ER α . super-activates at AP-1 but shows no increase of activity at an ERE.). Activity of the mutant and wild type hERs on a reporter gene driven by the human collagenase promoter including its AP-1 site (left) or of an isogenic reporter with an ERE substituted for the AP-1 site (right). *c*, ER α .K206A super-stimulates AP-1 activity in a variety of cell types. Shown is the fold estrogen induction of the collagenase promoter with AP-1 site in various transfected cells with either the wild type or K206A human ER. *d*, Mutation of AF-2 abolishes ER α .K206A stimulation at AP-1. Activity of K206A compared with a double mutant K206A: AF-2, on the collagenase promoter driven reporter gene.

Fig. 2 K14-ER α .K206A transgenic mice develop vaginal distortion and hypertrophy with age which cannot be explained by transgene expression levels. *a*, K14-ER α .K206A transgenic females develop perineal swelling (bottom, 12 months; compare to top, 17-months-old non-transgenic). *b*, Vaginal enlargement develops in K14-ER α .K206A transgenic (3rd and 4th panels) but not in non-transgenic (1st panel) or wild type ER α transgenic (2nd panel) mice. *c*, Aged K14-ER α .K206A mice develop redundant and distorted vaginas with hypertrophic squamous epithelium (top, 20x). This is not due to excessive transgene expression as shown by anti-huER α IHC (antibody: D75): Immunoreactivity in K14-ER α .K206A vaginal epithelium is rarely present in basal cell nuclei, whereas in wild type ER α transgenic vaginal epithelium, huER α immunoreactive basal cells are widespread. Endogenous murine ER α does not cross react with D75 (compare FVB/n to ER α and ER α .K206A) (200x).

Fig. 3 Vaginal epithelial hyperplasia in K14-ER α .K206A transgenic mice is associated with greater numbers of proliferating cells compared to wild type K14-ER α transgenic animals. *a*, Vaginal and cervical epithelia of K14-ER α .K206A transgenic mice contain more cell layers than do non-transgenic animals (FVB/n). *b*, In 12-months-old K14-ER α .K206A transgenic vaginal tissue, PCNA

immunoreactivity is more intense than in age-matched wild type ER α and non-transgenic control mice, and the number of positive cell layers can reach ≥ 5 (400x). *c*, Cyclin D1 immunoreactivity of 12-months-old K14-ER α .K206A vaginal epithelium is markedly stronger than that of transgenic and non-transgenic control tissues.

Supplement Figure In non-transgenic mice in full estrus, Cyclin D1 immunoreactivity does not reach that seen in K14-ER α .K206A. *a*, Squamous epithelium shows high proliferative activity in mice in estrus as indicated by abundant mitotic cells. *b*, In accordance with epithelial proliferation, non-transgenic mice in estrus display a high number of Cyclin D1-positive cells. Staining intensity is comparable to that seen in K14-ER α transgenic mice, but is significantly lower than in K14-ER α .K206A transgenic epithelium (compare Fig. 3*c*). *c*, Non-transgenic cervical stroma of animals in estrus is devoid of Cyclin D1-positive cells.


References

1. Webb, P., Lopez, G.N., Uht, R.M. & Kushner, P.J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. *Mol Endocrinol* 9:443-456 (1995).
2. Webb, P., Nguyen, P., Valentine, C., Lopez, G. & al., e. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. *MOLECULAR ENDOCRINOLOGY* 13, 1672-1685 (1999).
3. Paech, K. *et al.* Differential ligand activation of estrogen receptors ER α and ER β at AP1 sites. *Science* 277, 1508-1510 (1997).
4. Saville, B. *et al.* Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. *Journal of Biological Chemistry* 275, 5379-5387 (2000).
5. Montano, M.M. & Katzenellenbogen, B.S. The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens. *Proc Natl Acad Sci USA* 94, 2581-2586 (1997).

6. Altucci, L. *et al.* 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. *Oncogene* **12**, 2315-2324 (1996).
7. Sabbah, M., Courilleau, D., Mester, J. & Redeuilh, G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. *Proceedings of the National Academy of Sciences of the United States of America* **96**, 11217-11222 (1999).
8. Starr, D.B., Matsui, W., Thomas, J.R. & Yamamoto, K.R. Intracellular receptors use a common mechanism to interpret signaling information at response elements. *Genes Dev* **10**, 1271-1283 (1996).
9. Philips, A., Chalbos, D. & Rochefort, H. Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. *J Biol Chem* **268**, 14103-14108 (1993).
10. Philips, A. *et al.* FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. *Molecular Endocrinology* **12**, 973-985 (1998).

Figure 1 A, B, C

A




C

Change Affinity interaction w ERα


Cell Line	ERα		ERα.K206A	
	-	+	-	+
HeLa	2.0	4.8	0.9	165.2
Ishikawa	3.2	3.6	3.6	78.3
MDA-MB	0.7	1.7	0.4	128.9
MCF-7	1.6	2.1	0.8	4.3
ChEF	0.8	1.0	0.1	0.9
GHT1-5	0.7	1.1	1.8	70.8

?

B



D.



less v400 on beta gel

Figure 1D

cellular








Figure 2




FVB/n

ERα

ERα.K206A

Figure 3

a



b

FVB/n

ERα

ERα.K206A

PCNA

c

CyclinD
vag Epi

CyclinD
Stroma





DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MD 21702-5012

REPLY TO
ATTENTION OF

MCMR-RMI-S (70-1y)

15 May 03


MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.
2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB266022	ADB265793
ADB260153	ADB281613
ADB272842	ADB284934
ADB283918	ADB263442
ADB282576	ADB284977
ADB282300	ADB263437
ADB285053	ADB265310
ADB262444	ADB281573
ADB282296	ADB250216
ADB258969	ADB258699
ADB269117	ADB274387
ADB283887	ADB285530
ADB263560	
ADB262487	
ADB277417	
ADB285857	
ADB270847	
ADB283780	
ADB262079	
ADB279651	
ADB253401	
ADB264625	
ADB279639	
ADB263763	
ADB283958	
ADB262379	
ADB283894	
ADB283063	
ADB261795	
ADB263454	
ADB281633	
ADB283877	
ADB284034	
ADB283924	
ADB284320	
ADB284135	
ADB259954	
ADB258194	
ADB266157	
ADB279641	
ADB244802	
ADB257340	
ADB244688	
ADB283789	
ADB258856	
ADB270749	
ADB258933	